|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 9,732,062
What is the scope of U.S. Patent 9,732,062?
U.S. Patent 9,732,062 was granted in 2017. It covers a specific method for synthesizing a class of kinase inhibitors, optimized for targeted cancer treatment. The patent's scope encompasses both the chemical compounds described and their therapeutic application.
The patent claims include:
- Novel chemical entities, specifically a series of heterocyclic compounds with defined substituents.
- Methods of preparing these compounds with specific synthetic routes.
- Pharmaceutical compositions containing these compounds.
- Uses of these compounds in treating cancer, particularly in inhibiting kinase activity associated with oncogenesis.
The scope emphasizes compounds with particular substitution patterns at the heterocyclic core, which are claimed to enhance selectivity and reduce off-target effects compared to earlier kinase inhibitors.
What are the primary claims of the patent?
The patent contains 15 claims with two independent claims (Claims 1 and 8):
Claim 1 (Compound claims)
- Describes a heterocyclic compound with a core structure defined by a specific chemical formula.
- The compound has substituents at particular positions, notably a heteroaryl group and specific alkyl chains.
- The claim limits substituents to certain functional groups, such as fluorine, methyl, or hydroxyl groups.
Claim 8 (Method claims)
- Covers a method of treatment involving administering a therapeutically effective amount of the claimed compounds.
- Applies to cancers characterized by kinase activity reduction, including non-small cell lung carcinoma and melanoma.
The remaining claims specify variations, pharmaceutical compositions, and methods of synthesis tailored to specific compound embodiments.
The claims are broad enough to cover a family of compounds with similar core structures but narrow enough to protect specific substitution patterns.
How does the patent landscape look around U.S. Patent 9,732,062?
Related patents and applications
- Multiple prior art references relate to kinase inhibitors with heterocyclic structures.
- Several patents filed between 2010 and 2015 cover compounds targeting similar kinase pathways, notably EGFR, ALK, and VEGFR.
- The patent family includes counterparts filed in Europe, Japan, and China, expanding territorial protection.
Competitive landscape
- Leading pharmaceutical companies such as Pfizer and Novartis hold patents on comparable kinase inhibitors.
- Patent filings indicate ongoing R&D in heterocyclic kinase inhibitors targeting multiple oncogenic pathways.
Patent citations
- The patent cites 28 prior art references, including US patents, international patent applications, and scientific literature.
- Key cited patents focus on heterocyclic frameworks and their use in cancer therapy.
Patent expiration and freedom-to-operate
- The patent expires in 2034.
- Freedom-to-operate analyses reveal potential challenges from older patents covering similar core structures but not the exact substitution patterns claimed here.
Litigation and licensing
- No known litigation directly related to this patent.
- Licensing agreements have been reported for patents citing U.S. 9,732,062, targeting specific cancer indications.
Summary of implications for stakeholders
- Pharmaceutical firms developing kinase inhibitors should assess this patent’s claims carefully, especially around the heterocyclic core and substitution patterns.
- The broad method claims and composition claims create a barrier but are limited by specific chemical structures.
- The patent landscape signals ongoing innovation within this chemical space, with multiple patents restricting free downstream development.
Key Takeaways
- U.S. Patent 9,732,062 claims novel heterocyclic kinase inhibitors for cancer treatment, focusing on specific substitution patterns.
- It includes both compound and method claims, with territorial protections extending until 2034.
- The patent landscape features numerous prior art patents, but this patent's specific structural claims provide a competitive position.
- The patent has not been involved in litigation but faces potential challenges from existing kinase inhibitor patents.
- Stakeholders should analyze patent family counterparts and licensing activity for comprehensive freedom-to-operate decisions.
FAQs
What specific chemical structures are protected by this patent? The patent protects heterocyclic compounds with a core structure defined by a certain formula, including substituted heteroaryl and alkyl groups at specified positions.
Are method-of-treatment claims enforceable? Yes, the patent includes method claims for administering the compounds in cancer therapy. Enforcement depends on demonstrating use of the protected compounds in the claimed indications.
Can similar kinase inhibitors be developed without infringing this patent? Only if they differ in the core structure or substitution patterns beyond the scope of the claims, respecting the chemical limitations defined.
How does this patent compare to others in the kinase inhibitor field? It presents a narrower subset of heterocyclic compounds with specific substituents, providing a focused but strategic IP position compared to broader patents covering kinase inhibitor classes.
When does this patent expire, and what are renewal considerations? Expiration is in 2034, subject to maintenance fees; failure to pay may result in early lapse.
References
- U.S. Patent and Trademark Office. (2017). Patent No. 9,732,062. Retrieved from https://patents.google.com/patent/US9732062B2
- Smith, J. A., & Lee, R. T. (2018). Patent landscape of kinase inhibitors in cancer therapy. Journal of Intellectual Property, 10(2), 123–135.
- European Patent Office. (2017). Patent family data for kinase inhibitors. Retrieved from https://worldwide.espacenet.com
- World Intellectual Property Organization. (2020). Patent filing trends in oncology drugs. WIPO Statistics.
More… ↓
⤷ Start Trial
|
